Trial Outcomes & Findings for Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies (NCT NCT01796470)

Last Updated: 2020-06-02

Results Overview

ORR assessed by the Independent Review Committee (IRC), was based on the International Working Group Revised Response Criteria (Cheson, 2012) and investigator's response, defined as the percentage of participants achieving a complete response (CR) or partial response (PR) (or very good partial response \[VGPR\] or minor response \[MR\] for participants with LPL/WM). CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. VGPR and MR were defined as ≥ 90% and ≥ 25% but \< 50% decrease from baseline in serum monoclonal immunoglobulin M (IgM) concentration by serum protein electrophoresis (SPEP) respectively.

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

66 participants

Primary outcome timeframe

Start of treatment to end of treatment (Up to 18 months)

Results posted on

2020-06-02

Participant Flow

Participants were enrolled at study sites in the United States. The first participant was screened on 20 June 2013. The last study visit occurred on 22 December 2016.

85 participants were screened.

Participant milestones

Participant milestones
Measure	Entospletinib + Idelalisib CLL Participants with a documented diagnosis of chronic lymphocytic leukemia (CLL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib iNHL: FL Participants with a documented diagnosis of indolent non-Hodgkin lymphoma (iNHL) with follicular lymphoma (FL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib DLBCL Participants with a documented diagnosis of diffuse large B-cell lymphoma (DLBCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred ,increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib MCL Participants with a documented diagnosis of mantle cell lymphoma (MCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib iNHL: Others Participants with a documented diagnosis of iNHL with other subtypes lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), small lymphocytic lymphoma (SLL), and marginal zone lymphoma (MZL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) increased to 600 mg/100 mg for 2 weeks, if no DLT increased to 800 mg/100 mg for 4 weeks, if no DLT increased to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.
Overall Study STARTED	35	14	6	3	8
Overall Study Entospletinib Monotherapy	4	4	0	0	0
Overall Study COMPLETED	0	0	0	0	0
Overall Study NOT COMPLETED	35	14	6	3	8

Reasons for withdrawal

Reasons for withdrawal
Measure	Entospletinib + Idelalisib CLL Participants with a documented diagnosis of chronic lymphocytic leukemia (CLL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib iNHL: FL Participants with a documented diagnosis of indolent non-Hodgkin lymphoma (iNHL) with follicular lymphoma (FL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib DLBCL Participants with a documented diagnosis of diffuse large B-cell lymphoma (DLBCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred ,increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib MCL Participants with a documented diagnosis of mantle cell lymphoma (MCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib iNHL: Others Participants with a documented diagnosis of iNHL with other subtypes lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), small lymphocytic lymphoma (SLL), and marginal zone lymphoma (MZL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) increased to 600 mg/100 mg for 2 weeks, if no DLT increased to 800 mg/100 mg for 4 weeks, if no DLT increased to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.
Overall Study Adverse Event	4	2	2	1	3
Overall Study Death	2	0	0	0	1
Overall Study Initiated New Therapy	9	0	0	0	2
Overall Study Lost to Follow-up	0	1	0	0	0
Overall Study Physician Decision	5	4	1	0	1
Overall Study Progressive Disease	7	7	3	2	0
Overall Study Protocol Criteria for Withdrawal	1	0	0	0	0
Overall Study Withdrawal by Subject	7	0	0	0	1

Baseline Characteristics

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Entospletinib + Idelalisib CLL n=35 Participants Participants with a documented diagnosis of chronic lymphocytic leukemia (CLL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib iNHL: FL n=14 Participants Participants with a documented diagnosis of indolent non-Hodgkin lymphoma (iNHL) with follicular lymphoma (FL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months	Entospletinib + Idelalisib DLBCL n=6 Participants Participants with a documented diagnosis of diffuse large B-cell lymphoma (DLBCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred ,increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib MCL n=3 Participants Participants with a documented diagnosis of mantle cell lymphoma (MCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib iNHL: Others n=8 Participants Participants with a documented diagnosis of iNHL with other subtypes lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), small lymphocytic lymphoma (SLL) and marginal zone lymphoma (MZL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) increased to 600 mg/100 mg for 2 weeks, if no DLT increased to 800 mg/100 mg for 4 weeks, if no DLT increased to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Total n=66 Participants Total of all reporting groups
Age, Continuous	68 years STANDARD_DEVIATION 12.9 • n=5 Participants	64 years STANDARD_DEVIATION 13.4 • n=7 Participants	69 years STANDARD_DEVIATION 17.4 • n=5 Participants	62 years STANDARD_DEVIATION 10.8 • n=4 Participants	69 years STANDARD_DEVIATION 8.9 • n=21 Participants	67 years STANDARD_DEVIATION 12.7 • n=10 Participants
Sex: Female, Male Female	15 Participants n=5 Participants	6 Participants n=7 Participants	4 Participants n=5 Participants	1 Participants n=4 Participants	5 Participants n=21 Participants	31 Participants n=10 Participants
Sex: Female, Male Male	20 Participants n=5 Participants	8 Participants n=7 Participants	2 Participants n=5 Participants	2 Participants n=4 Participants	3 Participants n=21 Participants	35 Participants n=10 Participants
Race/Ethnicity, Customized Ethnicity · Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Race/Ethnicity, Customized Ethnicity · Not Hispanic or Latino	35 Participants n=5 Participants	12 Participants n=7 Participants	6 Participants n=5 Participants	3 Participants n=4 Participants	8 Participants n=21 Participants	64 Participants n=10 Participants
Race/Ethnicity, Customized Ethnicity · Not Permitted	0 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=10 Participants
Race/Ethnicity, Customized Race · White/Caucasian	27 Participants n=5 Participants	11 Participants n=7 Participants	6 Participants n=5 Participants	3 Participants n=4 Participants	8 Participants n=21 Participants	55 Participants n=10 Participants
Race/Ethnicity, Customized Race · Black or African American	5 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	6 Participants n=10 Participants
Race/Ethnicity, Customized Race · Native Hawaiian or Other Pacific Islander	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants
Race/Ethnicity, Customized Race · Asian	2 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=10 Participants
Race/Ethnicity, Customized Race · Other	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants
Race/Ethnicity, Customized Race · Not Reported	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants
Karnofsky Performance Status 40	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants
Karnofsky Performance Status 50	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants
Karnofsky Performance Status 60	2 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	3 Participants n=10 Participants
Karnofsky Performance Status 70	2 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	4 Participants n=10 Participants
Karnofsky Performance Status 80	9 Participants n=5 Participants	7 Participants n=7 Participants	2 Participants n=5 Participants	1 Participants n=4 Participants	5 Participants n=21 Participants	24 Participants n=10 Participants
Karnofsky Performance Status 90	14 Participants n=5 Participants	4 Participants n=7 Participants	3 Participants n=5 Participants	1 Participants n=4 Participants	3 Participants n=21 Participants	25 Participants n=10 Participants
Karnofsky Performance Status 100	6 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	8 Participants n=10 Participants

PRIMARY outcome

Timeframe: Start of treatment to end of treatment (Up to 18 months)

Population: The study was terminated due to safety measures. Complete data was not collected for any participant.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: First dose date up to the last dose date plus 30 days (maximum duration: 19 months)

Population: The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).

A treatment-emergent Adverse Event (AE) was defined as any AE with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drugs or an AE leading to premature discontinuation of study drug. An AE is any untoward medical occurrence in a clinical investigation where participants administered a medicinal product, and which does not necessarily have a causal relationship with this treatment.

Outcome measures

Outcome measures
Measure	Entospletinib + Idelalisib CLL n=35 Participants Participants with a documented diagnosis of chronic lymphocytic leukemia (CLL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib iNHL: FL n=14 Participants Participants with a documented diagnosis of indolent non-Hodgkin lymphoma (iNHL) with follicular lymphoma (FL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib DLBCL n=6 Participants Participants with a documented diagnosis of diffuse large B-cell lymphoma (DLBCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred ,increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib MCL n=3 Participants Participants with a documented diagnosis of mantle cell lymphoma (MCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib iNHL: Others n=8 Participants Participants with a documented diagnosis of iNHL with other subtypes lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), small lymphocytic lymphoma (SLL) and marginal zone lymphoma (MZL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) increased to 600 mg/100 mg for 2 weeks, if no DLT increased to 800 mg/100 mg for 4 weeks, if no DLT increased to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.
Percentage of Participants Experiencing Treatment-Emergent Adverse Events	100 percentage of participants	100 percentage of participants	100 percentage of participants	100 percentage of participants	100 percentage of participants

SECONDARY outcome

Timeframe: First dose date up to the last dose date plus 30 days (maximum: 18 months)

Population: Participants in the Safety Analysis Set were analyzed.

A treatment-emergent laboratory (Hematology, Serum Chemistry and Urinalysis) abnormality was defined as an abnormality that, compared to baseline, worsens by ≥ 1 grade in the period from the first dose of study drug. Safety as assessed by grading of laboratory values and AEs according to the National Cancer Institutes' Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Grade 0 = none, Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening or disabling. If baseline data are missing, then any graded abnormality (i.e., an abnormality that is Grade ≥ 1 in severity) will be considered treatment-emergent. The percentage of participants in each worst postbaseline grade is reported.

Outcome measures

Outcome measures
Measure	Entospletinib + Idelalisib CLL n=35 Participants Participants with a documented diagnosis of chronic lymphocytic leukemia (CLL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib iNHL: FL n=14 Participants Participants with a documented diagnosis of indolent non-Hodgkin lymphoma (iNHL) with follicular lymphoma (FL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib DLBCL n=6 Participants Participants with a documented diagnosis of diffuse large B-cell lymphoma (DLBCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred ,increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib MCL n=3 Participants Participants with a documented diagnosis of mantle cell lymphoma (MCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib iNHL: Others n=8 Participants Participants with a documented diagnosis of iNHL with other subtypes lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), small lymphocytic lymphoma (SLL) and marginal zone lymphoma (MZL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) increased to 600 mg/100 mg for 2 weeks, if no DLT increased to 800 mg/100 mg for 4 weeks, if no DLT increased to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities ALP Increased (Grade 3)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Neutrophils Count Decreased (Grade 1)	17.1 percentage of participants	21.4 percentage of participants	0 percentage of participants	66.7 percentage of participants	25.0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Neutrophils Count Decreased (Grade 2)	20.0 percentage of participants	14.3 percentage of participants	0 percentage of participants	0 percentage of participants	25.0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Neutrophils Count Decreased (Grade 3)	14.3 percentage of participants	7.1 percentage of participants	16.7 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Neutrophils Count Decreased (Grade 4)	11.4 percentage of participants	7.1 percentage of participants	0 percentage of participants	0 percentage of participants	25.0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Anemia (Grade 1)	20.0 percentage of participants	35.7 percentage of participants	16.7 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Anemia (Grade 2)	14.3 percentage of participants	7.1 percentage of participants	16.7 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Anemia (Grade 3)	5.7 percentage of participants	0 percentage of participants	16.7 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Anemia (Grade 4)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Leukocytosis (Grade 1)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Leukocytosis (Grade 2)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Leukocytosis (Grade 3)	28.6 percentage of participants	0 percentage of participants	0 percentage of participants	33.3 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Leukocytosis (Grade 4)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities White Blood Cell Count Decreased (Grade 1)	0 percentage of participants	21.4 percentage of participants	16.7 percentage of participants	0 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities WBC Count Decreased (Grade 2)	14.3 percentage of participants	0 percentage of participants	16.7 percentage of participants	33.3 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities WBC Count Decreased (Grade 3)	5.7 percentage of participants	14.3 percentage of participants	0 percentage of participants	0 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities WBC Count Decreased (Grade 4)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Lymphocyte Count Decreased (Grade 1)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Lymphocyte Count Decreased (Grade 2)	0 percentage of participants	0 percentage of participants	16.7 percentage of participants	33.3 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Lymphocyte Count Decreased (Grade 3)	5.7 percentage of participants	21.4 percentage of participants	50.0 percentage of participants	0 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Lymphocyte Count Decreased (Grade 4)	0 percentage of participants	0 percentage of participants	0 percentage of participants	33.3 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Lymphocyte Count Increased (Grade 1)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Lymphocyte Count Increased (Grade 2)	8.6 percentage of participants	7.1 percentage of participants	16.7 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Lymphocyte Count Increased (Grade 3)	28.6 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Lymphocyte Count Increased (Grade 4)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Platelets Count Decreased (Grade 1)	11.4 percentage of participants	28.6 percentage of participants	16.7 percentage of participants	33.3 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Platelets Count Decreased (Grade 2)	2.9 percentage of participants	7.1 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Platelets Count Decreased (Grade 3)	5.7 percentage of participants	14.3 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Platelets Count Decreased (Grade 4)	2.9 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Alanine Aminotransferase (ALT) Increased (Grade 1)	22.9 percentage of participants	7.1 percentage of participants	33.3 percentage of participants	0 percentage of participants	50.0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities ALT Increased (Grade 2)	8.6 percentage of participants	7.1 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities ALT Increased (Grade 3)	0 percentage of participants	35.7 percentage of participants	16.7 percentage of participants	33.3 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities ALT Increased (Grade 4)	5.7 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypoalbuminemia (Grade 1)	14.3 percentage of participants	28.6 percentage of participants	0 percentage of participants	0 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypoalbuminemia (Grade 2)	5.7 percentage of participants	0 percentage of participants	16.7 percentage of participants	33.3 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypoalbuminemia (Grade 3)	0 percentage of participants	0 percentage of participants	16.7 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypoalbuminemia (Grade 4)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Alkaline Phosphatase (ALP) Increased (Grade 1)	17.1 percentage of participants	28.6 percentage of participants	33.3 percentage of participants	33.3 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities ALP Increased (Grade 2)	2.9 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities ALP Increased (Grade 4)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Aspartate Aminotransferase (AST)Increased(Grade 1)	20.0 percentage of participants	14.3 percentage of participants	50.0 percentage of participants	0 percentage of participants	37.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities AST Increased (Grade 2)	2.9 percentage of participants	14.3 percentage of participants	0 percentage of participants	33.3 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities AST Increased (Grade 3)	0 percentage of participants	28.6 percentage of participants	16.7 percentage of participants	0 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities AST Increased (Grade 4)	5.7 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Chronic Kidney Disease (Grade 1)	34.3 percentage of participants	42.9 percentage of participants	50.0 percentage of participants	33.3 percentage of participants	37.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Chronic Kidney Disease (Grade 2)	0 percentage of participants	7.1 percentage of participants	33.3 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Chronic Kidney Disease (Grade 3)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Chronic Kidney Disease (Grade 4)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hyperglycemia (Grade 1)	11.4 percentage of participants	7.1 percentage of participants	0 percentage of participants	0 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hyperglycemia (Grade 2)	5.7 percentage of participants	7.1 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hyperglycemia (Grade 3)	11.4 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hyperglycemia (Grade 4)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypoglycemia (Grade 1)	0 percentage of participants	14.3 percentage of participants	0 percentage of participants	33.3 percentage of participants	25.0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypoglycemia (Grade 2)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypoglycemia (Grade 3)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypoglycemia (Grade 4)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypophosphatemia (Grade 1)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypophosphatemia (Grade 2)	2.9 percentage of participants	7.1 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypophosphatemia (Grade 3)	5.7 percentage of participants	0 percentage of participants	16.7 percentage of participants	0 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypophosphatemia (Grade 4)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypokalemia (Grade 1)	20.0 percentage of participants	7.1 percentage of participants	33.3 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypokalemia (Grade 2)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypokalemia (Grade 3)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hypokalemia (Grade 4)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hyponatremia (Grade 1)	20.0 percentage of participants	0 percentage of participants	50.0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hyponatremia (Grade 2)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hyponatremia (Grade 3)	5.7 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	25.0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Hyponatremia (Grade 4)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Blood Bilirubin Increased (Grade 1)	17.1 percentage of participants	14.3 percentage of participants	50.0 percentage of participants	0 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Blood Bilirubin Increased (Grade 2)	25.7 percentage of participants	14.3 percentage of participants	16.7 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Blood Bilirubin Increased (Grade 3)	2.9 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Blood Bilirubin Increased (Grade 4)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Proteinuria (Grade 1)	22.9 percentage of participants	7.1 percentage of participants	0 percentage of participants	0 percentage of participants	12.5 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Proteinuria (Grade 2)	2.9 percentage of participants	14.3 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Proteinuria (Grade 3)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Proteinuria (Grade 4)	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants	0 percentage of participants

SECONDARY outcome

Timeframe: First dose (entospelinib + idelalisib) date up to 6 months

Population: The study was terminated due to safety measures. Complete data was not collected for any participant.

Maximum tolerated dose (MTD) is defined as the highest dose level that was consistently well tolerated without dose limiting toxicity (DLT) for the majority of participants time on treatment (ie,\> 50%) as determined by the investigator for each participant. DLTs are defined as Grade 4 hematological toxicities persisting for ≥ 14 days or Grade ≥ 3 toxicities of other types.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Start of treatment to end of treatment (Up to 18 months)

Population: The study was terminated due to safety measures. Complete data was not collected for any participant.

PFS was defined as the interval from the first dose of study drug to the earlier of the first documentation of definitive disease progression or death from any cause.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Start of treatment to end of treatment (Up to 18 months)

Population: The study was terminated due to safety measures. Complete data was not collected for any participant.

DOR was defined as the interval from the first-time response (CR or PR \[or VGPR or MR for participants with LPL/WM\]) is achieved to the earlier of the first documentation of definitive disease progression or death from any cause.CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. VGPR and MR were defined as ≥ 90% and ≥ 25% but \< 50% decrease from baseline in serum monoclonal IgM concentration by SPEP respectively.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Start of treatment to end of treatment (Up to 18 months)

Population: The study was terminated due to safety measures. Complete data was not collected for any participant.

TTR was defined as the interval from the first dose of entospletinib/idelalisib to the time response (CR or PR \[or VGPR or MR for participants with LPL/WM\]) is first achieved. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. VGPR and MR were defined as ≥ 90% and ≥ 25% but \< 50% decrease from baseline in serum monoclonal IgM concentration by SPEP respectively.

Outcome measures

Outcome data not reported

Adverse Events

Entospletinib + Idelalisib CLL

Serious events: 24 serious events

Other events: 34 other events

Deaths: 3 deaths

Entospletinib + Idelalisib iNHL: FL

Serious events: 2 serious events

Other events: 14 other events

Deaths: 1 deaths

Entospletinib + Idelalisib DLBCL

Serious events: 4 serious events

Other events: 6 other events

Deaths: 2 deaths

Entospletinib + Idelalisib MCL

Serious events: 2 serious events

Other events: 3 other events

Deaths: 2 deaths

Entospletinib + Idelalisib iNHL: Others

Serious events: 5 serious events

Other events: 8 other events

Deaths: 2 deaths

Serious adverse events

Serious adverse events
Measure	Entospletinib + Idelalisib CLL n=35 participants at risk Participants with a documented diagnosis of chronic lymphocytic leukemia (CLL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib iNHL: FL n=14 participants at risk Participants with a documented diagnosis of indolent non-Hodgkin lymphoma (iNHL) with follicular lymphoma (FL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib DLBCL n=6 participants at risk Participants with a documented diagnosis of diffuse large B-cell lymphoma (DLBCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred ,increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib MCL n=3 participants at risk Participants with a documented diagnosis of mantle cell lymphoma (MCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib iNHL: Others n=8 participants at risk Participants with a documented diagnosis of iNHL with other subtypes lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), small lymphocytic lymphoma (SLL), and marginal zone lymphoma (MZL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) increased to 600 mg/100 mg for 2 weeks, if no DLT increased to 800 mg/100 mg for 4 weeks, if no DLT increased to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.
Blood and lymphatic system disorders Febrile neutropenia	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	25.0% 2/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Abdominal pain	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Abdominal pain upper	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Diarrhoea	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
General disorders Drug interaction	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
General disorders Pyrexia	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Bacteraemia	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Bronchopulmonary aspergillosis	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Fungal infection	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Lung infection	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 1/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Pneumonia	14.3% 5/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Sepsis	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	25.0% 2/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations Alanine aminotransferase increased	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations Aspartate aminotransferase increased	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations Blood bilirubin increased	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations International normalised ratio increased	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations Lymphocyte count increased	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Nervous system disorders Altered state of consciousness	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Nervous system disorders Cerebrovascular accident	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Psychiatric disorders Confusional state	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Renal and urinary disorders Hydronephrosis	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Dyspnoea	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 1/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Hypoxia	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Pneumonitis	22.9% 8/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 2/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Respiratory failure	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Skin and subcutaneous tissue disorders Erythema multiforme	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Vascular disorders Deep vein thrombosis	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).

Other adverse events

Other adverse events
Measure	Entospletinib + Idelalisib CLL n=35 participants at risk Participants with a documented diagnosis of chronic lymphocytic leukemia (CLL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib iNHL: FL n=14 participants at risk Participants with a documented diagnosis of indolent non-Hodgkin lymphoma (iNHL) with follicular lymphoma (FL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib DLBCL n=6 participants at risk Participants with a documented diagnosis of diffuse large B-cell lymphoma (DLBCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred ,increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib MCL n=3 participants at risk Participants with a documented diagnosis of mantle cell lymphoma (MCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.	Entospletinib + Idelalisib iNHL: Others n=8 participants at risk Participants with a documented diagnosis of iNHL with other subtypes lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), small lymphocytic lymphoma (SLL), and marginal zone lymphoma (MZL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) increased to 600 mg/100 mg for 2 weeks, if no DLT increased to 800 mg/100 mg for 4 weeks, if no DLT increased to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months.
Blood and lymphatic system disorders Anaemia	14.3% 5/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 2/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Blood and lymphatic system disorders Increased tendency to bruise	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Blood and lymphatic system disorders Leukopenia	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Blood and lymphatic system disorders Lymphadenopathy	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Blood and lymphatic system disorders Lymphopenia	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Blood and lymphatic system disorders Neutropenia	11.4% 4/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Blood and lymphatic system disorders Pancytopenia	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Blood and lymphatic system disorders Thrombocytopenia	8.6% 3/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	14.3% 2/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Cardiac disorders Atrial fibrillation	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Cardiac disorders Palpitations	8.6% 3/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Cardiac disorders Supraventricular tachycardia	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Cardiac disorders Tachycardia	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Ear and labyrinth disorders Ear pain	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Abdominal pain	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Abdominal pain upper	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Abdominal tenderness	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Chapped lips	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Constipation	31.4% 11/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	14.3% 2/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 2/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Diarrhoea	40.0% 14/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	14.3% 2/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 2/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Dyschezia	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Dyspepsia	8.6% 3/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	28.6% 4/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Dysphagia	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Faeces soft	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Flatulence	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Gastritis	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Gastrooesophageal reflux disease	22.9% 8/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 2/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 1/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	25.0% 2/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Gingival pain	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Mouth ulceration	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Nausea	40.0% 14/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	50.0% 7/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	66.7% 4/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 1/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Oral discomfort	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Stomatitis	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	25.0% 2/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Gastrointestinal disorders Vomiting	14.3% 5/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	14.3% 2/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 2/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
General disorders Asthenia	8.6% 3/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
General disorders Catheter site pain	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
General disorders Chest discomfort	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
General disorders Chest pain	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	14.3% 2/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
General disorders Chills	20.0% 7/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	50.0% 3/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
General disorders Discomfort	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
General disorders Fatigue	42.9% 15/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	42.9% 6/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	66.7% 4/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	37.5% 3/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
General disorders Malaise	8.6% 3/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
General disorders Mucosal inflammation	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
General disorders Oedema peripheral	14.3% 5/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
General disorders Pain	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
General disorders Peripheral swelling	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
General disorders Pyrexia	28.6% 10/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	35.7% 5/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	83.3% 5/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 1/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Hepatobiliary disorders Cholelithiasis	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Hepatobiliary disorders Hyperbilirubinaemia	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Hepatobiliary disorders Jaundice	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Immune system disorders Hypogammaglobulinaemia	11.4% 4/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Cellulitis	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 1/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Conjunctivitis	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Herpes zoster	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Localised infection	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Mucosal infection	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Nasopharyngitis	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Oesophageal candidiasis	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Oral candidiasis	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Pharyngitis streptococcal	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Pyelonephritis	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Respiratory tract infection	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Sinusitis	14.3% 5/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Infections and infestations Upper respiratory tract infection	17.1% 6/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Injury, poisoning and procedural complications Contusion	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Injury, poisoning and procedural complications Periorbital haematoma	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations Alanine aminotransferase increased	17.1% 6/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	28.6% 4/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 1/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	25.0% 2/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations Aspartate aminotransferase increased	20.0% 7/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	28.6% 4/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	25.0% 2/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations Blood alkaline phosphatase increased	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 2/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations Blood bilirubin increased	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations Blood creatinine increased	11.4% 4/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations Blood glucose increased	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations International normalised ratio abnormal	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations Neutrophil count decreased	11.4% 4/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations Urine output decreased	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations Weight decreased	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Investigations White blood cell count decreased	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Metabolism and nutrition disorders Decreased appetite	14.3% 5/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	66.7% 4/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Metabolism and nutrition disorders Hyperuricaemia	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Metabolism and nutrition disorders Hypoalbuminaemia	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Metabolism and nutrition disorders Hypokalaemia	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Metabolism and nutrition disorders Hypomagnesaemia	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	25.0% 2/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Musculoskeletal and connective tissue disorders Arthralgia	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	21.4% 3/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 1/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Musculoskeletal and connective tissue disorders Joint swelling	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Musculoskeletal and connective tissue disorders Muscle spasms	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Musculoskeletal and connective tissue disorders Myalgia	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Musculoskeletal and connective tissue disorders Neck pain	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Musculoskeletal and connective tissue disorders Osteopenia	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Musculoskeletal and connective tissue disorders Pain in extremity	11.4% 4/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Nervous system disorders Dizziness	14.3% 5/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	14.3% 2/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Nervous system disorders Dysgeusia	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Nervous system disorders Headache	25.7% 9/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	28.6% 4/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	66.7% 2/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Nervous system disorders Hypoaesthesia	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Nervous system disorders Neuropathy peripheral	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Nervous system disorders Paraesthesia	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Nervous system disorders Peripheral sensory neuropathy	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Nervous system disorders Presyncope	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 1/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Nervous system disorders Syncope	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Psychiatric disorders Anxiety	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Psychiatric disorders Confusional state	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	14.3% 2/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Psychiatric disorders Depression	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Psychiatric disorders Insomnia	17.1% 6/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 2/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Psychiatric disorders Restlessness	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Psychiatric disorders Suicidal ideation	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Renal and urinary disorders Chromaturia	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Renal and urinary disorders Haematuria	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Renal and urinary disorders Nephrolithiasis	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Cough	28.6% 10/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	14.3% 2/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 1/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	25.0% 2/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Dysphonia	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Dyspnoea	11.4% 4/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	14.3% 2/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	66.7% 2/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	25.0% 2/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Lung infiltration	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Nasal congestion	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	14.3% 2/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 1/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Productive cough	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Sinus congestion	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Sneezing	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Throat irritation	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Throat tightness	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Respiratory, thoracic and mediastinal disorders Upper respiratory tract congestion	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Skin and subcutaneous tissue disorders Drug eruption	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Skin and subcutaneous tissue disorders Dry skin	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Skin and subcutaneous tissue disorders Eczema	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Skin and subcutaneous tissue disorders Erythema	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Skin and subcutaneous tissue disorders Hyperhidrosis	2.9% 1/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Skin and subcutaneous tissue disorders Night sweats	17.1% 6/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 2/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Skin and subcutaneous tissue disorders Pruritus	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Skin and subcutaneous tissue disorders Rash	20.0% 7/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 2/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Skin and subcutaneous tissue disorders Rash generalised	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Skin and subcutaneous tissue disorders Rash maculo-papular	5.7% 2/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	33.3% 1/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	25.0% 2/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Skin and subcutaneous tissue disorders Rash pruritic	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	14.3% 2/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Vascular disorders Flushing	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Vascular disorders Hypertension	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Vascular disorders Hypotension	8.6% 3/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	16.7% 1/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	12.5% 1/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
Vascular disorders Thrombophlebitis superficial	0.00% 0/35 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	7.1% 1/14 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/6 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/3 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).	0.00% 0/8 • First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years) The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).

Additional Information

Gilead Clinical Study Information Center

Gilead Sciences

Phone: 1-833-445-3230 (GILEAD-0)

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met: * The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or * The study has been completed at all study sites for at least 2 years
Publication restrictions are in place

Restriction type: OTHER